Miyatake H, Taki F, Taniguchi H, Suzuki R, Takagi K, Satake T
Second Department of Internal Medicine and Clinical Laboratory, Nagoya University School of Medicine, Japan.
Chest. 1991 Mar;99(3):670-3. doi: 10.1378/chest.99.3.670.
It has been demonstrated that bronchial hyperresponsiveness is a characteristic feature of bronchial asthma, and airway inflammation plays an important role in bronchial hyperresponsiveness. Erythromycin is an antibiotic extensively used worldwide which is also reported to have anti-inflammatory action. This study was designed to clarify whether erythromycin could favorably alter bronchial responsiveness in patients with bronchial asthma. To estimate bronchial responsiveness, histamine challenge was performed in 23 patients with bronchial asthma (atopic type, 11; nonatopic type, 12). All patients were treated for ten weeks with erythromycin, 200 mg three times daily, orally. After ten weeks' treatment, PC20, an index of bronchial sensitivity, was increased significantly. There was no difference between atopic and nonatopic patients in the improvement of PC20. It was concluded that erythromycin reduces the severity of bronchial responsiveness in patients with bronchial asthma.
已经证实，支气管高反应性是支气管哮喘的一个特征性表现，气道炎症在支气管高反应性中起重要作用。红霉素是一种在全球广泛使用的抗生素，也有报道称其具有抗炎作用。本研究旨在阐明红霉素是否能改善支气管哮喘患者的支气管反应性。为评估支气管反应性，对23例支气管哮喘患者（特应性类型11例，非特应性类型12例）进行了组胺激发试验。所有患者口服红霉素，每日3次，每次200mg，治疗10周。治疗10周后，支气管敏感性指标PC20显著升高。特应性和非特应性患者在PC20改善方面无差异。得出的结论是，红霉素可降低支气管哮喘患者支气管反应性的严重程度。
